3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
OTHER
2
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
18
Breast Neoplasms
5
Philadelphia Chromosome
4
Leukemia
4
Neoplasms
3
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid
2
Bronchiolitis Obliterans Syndrome
2
Translocation, Genetic
1
Pathologic Processes
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Hematologic Diseases
1
Bone Marrow Diseases
1
Blast Crisis
1
Advanced Breast Cancer (Parts 1 and 2)
1
Interventions
nilotinib
4
Imatinib Mesylate
4
Dasatinib
4
troxacitabine
1
ponatinib
1
litronesib
1
exatecan
1
carfilzomib
1
bosutinib
1
blinatumomab
1
asciminib
1
TAK-901
1
STA 9090
1
Panobinostat
1
Homoharringtonine
1
Fentanyl
1
Dexamethasone
1
Decitabine
1
Calcium Dobesilate
1
2-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Blast Crisis
×
bosutinib
×
Clear all
NCT04877522
2026-06-10
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled